Consensus price targets issued by Wall Street equity analysts covering Tenaya Therapeutics establish a median 12-month target of $3.00 per share, with individual forecasts ranging from a conservative floor of $2.00 up to an upper bull-case ceiling of $8.00. These projections reflect anticipated upside potential tied directly to upcoming clinical trial milestones across its lead gene therapy candidates.